H. Lundbeck A S
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$93.3M
Doctors Paid
289
Transactions
8,279
2024 Total
$9.8M
Payment Breakdown by Category
Research$87.7M (94.0%)
Travel$1.8M (1.9%)
Food & Beverage$107,129 (0.1%)
Consulting$21,140 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $87.7M | 5,861 | 94.0% |
| Honoraria | $3.7M | 920 | 3.9% |
| Travel and Lodging | $1.8M | 925 | 1.9% |
| Food and Beverage | $107,129 | 519 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $37,643 | 43 | 0.0% |
| Consulting Fee | $21,140 | 11 | 0.0% |
Payments by Type
Research
$87.7M
5,861 transactions
General
$5.6M
2,418 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia DayBreak | $32.4M | 0 | 83 |
| Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder MDD | $5.9M | 0 | 127 |
| Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia Debut | $4.9M | 1 | 49 |
| A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE | $4.0M | 0 | 725 |
| Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine (RELIEF) | $3.4M | 0 | 124 |
| AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | $3.0M | 0 | 800 |
| Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder MDD | $2.7M | 7 | 82 |
| INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL-GROUP, SINGLE-ASCENDING ORAL DOSE TRIAL INVESTIGATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF LU AG12947 IN HEALTHY PARTICIPANTS WITH AN OPEN-LABEL CROSS-OVER PART TO INVESTIGATE INTRA-SUBJECT VARIABILITY AND EFFECT OF FOOD | $2.6M | 0 | 12 |
| Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia Anew | $2.6M | 0 | 32 |
| A Study Investigating Lu AG22515 in Healthy Adults | $2.6M | 1 | 3 |
| LU AF28996 IN PARTICIPANTS WITH PARKINSON'S DISEASE (PD) | $2.1M | 0 | 81 |
| Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension RESTORE | $1.6M | 3 | 142 |
| LU AG06466 IN PARTICIPANTS WITH POST TRAUMATIC STRESS DISORDER (PTSD) | $1.2M | 0 | 22 |
| A TRIAL INVESTIGATING LU AF28996 IN HEALTHY ADULT PARTICIPANTS | $1.2M | 0 | 4 |
| A STUDY INVESTIGATING THE MOVEMENT OF LU AG09222 INTO, THROUGH, AND OUT OF THE BODY OF HEALTHY CAUCASIAN, CHINESE, AND JAPANESE PARTICIPANTS | $1.2M | 0 | 14 |
| A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY | $1.2M | 0 | 583 |
| STUDY WITH LU AF87908 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ALZHEIMER'S DISEASE | $1.2M | 0 | 56 |
| A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | $945,001 | 0 | 168 |
| A Study Investigating Lu AG06474 in Healthy Young Participants | $916,144 | 1 | 1 |
| A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) | $814,121 | 0 | 192 |
| A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy | $802,705 | 0 | 343 |
| SUSTAINED EFFECT OF DROXIDOPA IN SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION (RESTORE) | $759,598 | 0 | 248 |
| INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | $670,037 | 0 | 132 |
| Long-term Safety and Tolerability of Idalopirdine Lu AE58054 as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimers Disease STAR Extension | $621,458 | 0 | 54 |
| A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) | $584,139 | 0 | 240 |
| INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE | $542,116 | 0 | 129 |
| Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) | $480,381 | 0 | 83 |
| A STUDY IN HEALTHY ADULTS INVESTIGATING EPTINEZUMAB PRODUCED BY 2 DIFFERENT MANUFACTURING CELL LINES | $402,971 | 0 | 6 |
| Real-life Effectiveness of Vortioxetine in Depression RELIEVE | $386,234 | 3 | 43 |
| SAFETY AND TOLERABILITY OF LU AG06474 IN HEALTHY YOUNG MEN | $377,195 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Jeffrey Levy, Md Phd, MD PHD | Internal Medicine | Hollywood, FL | $916,144 | $0 |
| Gregory Mattingly, M.d, M.D | Psychiatry | Saint Charles, MO | $442,921 | $0 |
| John Kane | Psychiatry | Glen Oaks, NY | $354,030 | $0 |
| Christoph Correll, Md, MD | Psychiatry | Glen Oaks, NY | $348,694 | $0 |
| Dr. Gustavo Alva, M.d, M.D | Psychiatry | Orange, CA | $273,983 | $0 |
| Peter Mcallister, M.d, M.D | Neurology | Fairfield, CT | $241,138 | $0 |
| Dr. Leslie Citrome, Md, Mph, MD, MPH | Psychiatry | Pomona, NY | $238,959 | $0 |
| Sumitha Reddy, Md, MD | Internal Medicine | Hamilton, NJ | $236,430 | $0 |
| Dr. Alireza Atri, Md Phd, MD PHD | Neurological Surgery | Boston, MA | $188,969 | $0 |
| Andrew Cutler, Md, MD | Psychiatry | Lakewood Ranch, FL | $163,569 | $0 |
| Deborah Tepper, Md, MD | Internal Medicine | Lebanon, NH | $125,322 | $0 |
| Dr. Andrew Blumenfeld, M.d, M.D | Neurology | Los Angeles, CA | $125,167 | $0 |
| Mr. Roueen Rafeyan, M.d, M.D | Addiction Medicine | Chicago, IL | $113,713 | $0 |
| Unknown Provider | — | — | $108,615 | $0 |
| Wolfgang Singer, M.d, M.D | Neurology | Rochester, MN | $102,263 | $0 |
| Dr. Stephen Stahl, Md, MD | Specialist | Carlsbad, CA | $96,847 | $0 |
| Dr. Michael Thase, Md, MD | Psychiatry | Philadelphia, PA | $85,210 | $0 |
| Dr. Ilan Melnick, M.d, M.D | Psychiatry | Coral Gables, FL | $83,586 | $0 |
| Peter Goadsby, Md, MD | Internal Medicine | Los Agneles, CA | $82,262 | $0 |
| Wade Cooper, Do, DO | Neurology | Ann Arbor, MI | $80,781 | $0 |
| Dr. Michael Banov, Md, MD | Psychiatry | Marietta, GA | $77,681 | $0 |
| P. Christopher Gottschalk, M.d, M.D | Neurology | Fairfield, CT | $68,710 | $0 |
| Dr. Roger Cady, Md, MD | Family Medicine | Springfield, MO | $65,833 | $0 |
| Dr. Amaal Starling, M.d, M.D | Neurology | Scottsdale, AZ | $60,546 | $0 |
| Rajiv Tandon, M.d, M.D | Psychiatry | Kalamazoo, MI | $57,120 | $0 |
Ad
Top Products
- VYEPTI $9.2M
- TRINTELLIX $8.9M
Associated Products (7)
- VYEPTI $15.7M
- TRINTELLIX $15.4M
- BRINTELLIX $7.0M
- Idalopirdine $56,870
- ESCITALOPRAM $29,900
- RASAGILINE $22,557
- EBIXA $20,533
Payment Categories
- Food & Beverage $107,129
- Consulting $21,140
- Travel & Lodging $1.8M
- Research $87.7M
About H. Lundbeck A S
H. Lundbeck A S has made $93.3M in payments to 289 healthcare providers, recorded across 8,279 transactions in the CMS Open Payments database. In 2024, the company paid $9.8M. The top product by payment volume is VYEPTI ($9.2M).
Payments were distributed across 44 medical specialties. The top specialty by payment amount is Psychiatry ($3.1M to 109 doctors).
Payment categories include: Food & Beverage ($107,129), Consulting ($21,140), Research ($87.7M), Travel & Lodging ($1.8M).
H. Lundbeck A S is associated with 7 products in the CMS Open Payments database, including VYEPTI, TRINTELLIX, and BRINTELLIX.